Paris, France

Paris Descartes University - Sorbonne Paris Cité , also known as "Paris V", is a public research university in Paris, France. It belongs to the leading academic alliance Sorbonne Paris Cité. It was established in order to succeed the medicine department of the world's second oldest academic institution, the University of Paris , shortly before the latter officially ceased to exist on December 31, 1970, as a consequence of the French cultural revolution of 1968, often referred to as "the French May". It is one of the best and the most prestigious French universities, mainly in the areas of medical science, biomedical science, law, computer science, economics and psychology.Headquartered in the historic École de Chirurgie in the 6th arrondissement of Paris, the university strongly focuses on medical science , biomedical science , social science , mathematics, computer science and law .A major pole of research and learning, Paris Descartes - Sorbonne Paris Cité is one of the most prestigious universities in France and the best one in its main domains. On that basis among others, it was rated by the 2013 QS World University Ranking 51-100th in Pharmacy and Pharmacology , 101-150th in Biological science , 100th in Medicine , 151-200th in Psychology , 151-200th in Linguistics , and 151-200th in Law .The University Paris Descartes supports a modern approach of social science on the basis of fieldwork, participant observation and ethnography . The dual master's degree in partnership with other important French academic institutions such as the École Normale Supérieure emphasizes opportunities offered as far as research is concerned.Faculty members have included eminent jurists, doctors and politicians. Wikipedia.


Time filter

Source Type

Patent
Institute Curie, French National Center for Scientific Research, French Institute of Health, Medical Research, Assistance Publique Hopitaux De Paris and University of Paris Descartes | Date: 2016-07-29

A composition that can be used as a vaccine containing means for targeting at least one antigen to dendritic cells and as adjuvants a granulocyte macrophage colony stimulating factor and a CpG oligodeoxynucleotide and/or a CpG-like oligodeoxynucleotide. This composition can used to treat cancers, infectious diseases caused by bacterial, viral, fungal, parasitic or protozoan infections, allergies and/or autoimmune diseases.


Patent
French Institute of Health, Medical Research, French National Center for Scientific Research, Genethon, University of Paris Descartes, École Nationale Supérieure de Chimie de Paris, University of Évry Val d'Essonne and Assistance Publique Hopitaux De Paris | Date: 2016-09-16

The present invention relates to a method for treating a Leber congenital amaurosis in a patient harbouring the mutation c.2991+1655 A>G in the CEP290 gene, comprising the step of administering to said patient at least one antisense oligonucleotide complementary to nucleic acid sequence that is necessary for preventing splicing of the cryptic exon inserted into the mutant c.2291+1655 A>G CEP290 mRNA


Patent
French Institute of Health, Medical Research, University of Paris Descartes, Fondation Imagine, Assistance Publique Hopitaux De Paris Aphp, French National Center for Scientific Research, University Grenoble Alpes, French Atomic Energy Commission and University of Burgundy | Date: 2015-02-18

The present invention relates to methods and pharmaceutical compositions for the treatment of diseases mediated by the NRP-1/OBR complex signaling pathway. In particular, the present invention relates to a method for treating a disease selected from the group consisting of cancers, obesity and obesity related diseases, anorexia, autoimmune diseases and infectious diseases in a subject in need thereof comprising administering the subject with a therapeutically effective amount of an antagonist of the NRP-1/OBR signaling pathway.


Patent
French Institute of Health, Medical Research, University of Paris Descartes and Assistance Publique Hopitaux De Paris Aphp | Date: 2015-04-29

The present invention relates to methods and pharmaceutical compositions for treating vaso-occlusive crises. In particular, the present invention relates to a method of treating a vaso-occlusive crisis in a subject in need thereof comprising administering to the subject a therapeutically effective amount of agent capable of degrading, destabilizing or depleting the blood-borne extracellular DNA from the blood of the subject.


Patent
Institute Pasteur Paris, French National Center for Scientific Research, University of Paris Descartes and Assistance Publique Hopitaux De Paris | Date: 2016-10-12

The present invention relates to polynucleotides enabling the rapid, simple and specific detection of Group B Streptococcus highly-virulent ST-17 clones. The present invention also relates to the polypeptides encoded by said polynucleotides, as well as to antibodies directed or raised against said polypeptides. The present invention also relates to kits and methods for the specific detection of Group B Streptococcus highly-virulent ST-17 clones, using the polynucleotides, the polypeptides or the antibodies according to the invention.


Patent
Institute Pasteur Paris and University of Paris Descartes | Date: 2017-01-11

The application relates to Listerin monocytogenes, more particularly to the determination of the clone to which a L. monocytogenes isolate belongs. The means of the application involve primers and/or probes, more particularly multiplex primers. The means of the application are notably useful to assess the invasivity that said L. monocytogenes isolate might show in a human being.


Patent
French Institute of Health, Medical Research, University Paris Diderot, University of Paris Descartes and Assistance Publique Hopitaux De Paris Aphp | Date: 2015-03-17

The present invention relates to method for predicting acute rejection in heart recipients. In particular, the present invention relates to a method for predicting acute rejection in a heart recipient comprising the steps consisting of i) determining the expression level (ELi) of at least one miRNAi selected from the group consisting of miR-155, miR-10a, miR-92a and miR-31 in a blood sample obtained from the heart recipient, ii) comparing the expression level (ELi) determined at step i) with a predetermined reference level (ELRi) and iii) and concluding that the recipient has a high risk of developing acute rejection when the level the expression level (ELi) determined at step i) is different (higher or lower) than the predetermined reference level (ELRi).


Patent
French Institute of Health, Medical Research, French National Center for Scientific Research, University of Paris Descartes, Fondation Imagine, University Paris Diderot, University Paris - Sud and Assistance Publique Hopitaux De Paris Aphp | Date: 2015-06-19

The present invention concerns a combination of (i) a DNA methylation inhibitor, and (ii) a Vitamin D receptor agonist, for simultaneous or sequential use in the treatment of a drug resistant cancer and/or in prevention of tumor relapse in a patient suffering from cancer. The present invention also relates to a combination of (i) a DNA methylation inhibitor, and (ii) a Vitamin D receptor agonist, for increasing, restoring or enhancing sensitivity of a patient suffering from cancer to a chemotherapeutic drug in a patient suffering from cancer.


Patent
French National Center for Scientific Research, University of Paris Descartes, French Institute of Health and Medical Research | Date: 2015-03-20

Today, despite current advances in combinatorial therapies such as surgery, radiotherapy and chemotherapy, aggressive cancers remain fatal. Cancer stem-like cells (CSCs) may account for chemotherapy resistance and thus represent a promising therapeutic target. In this context, the present inventors identified essential intracellular pathways favoring the self-renewal and survival of CSCs. More precisely, the present inventors showed that the cytokine co-receptor GP130 acts as a co-receptor for Apelin/APJ signaling and that the interaction of Apelin with APJ/GP130 activates a dual signaling pathway involving the Akt/mTOR and STAT3 transcription factor, thereby promoting CSCs survival and self-renewal. They therefore propose to block these pathways in order to treat patients suffering from tumors containing CSCs, such as glioblastomas. In another aspect, the invention relates to the use of the Apelin expression level for evaluating the survival probability of a subject suffering from glioblastoma.


Patent
Biovaxim Ltd and University of Paris Descartes | Date: 2017-05-31

The present invention relates to pharmaceutical compositions comprising a mixture of a specific HIV antigen and a non-pathogenic living bacterium. Said specific HIV antigen comprises one or more epitopes from Gag and/or Pol proteins and is preferably under a particulate form. Said bacterium is preferably Lactobacillus plantarum. These compositions are useful for preventing and/or treating an HIV disease in humans.

Loading University of Paris Descartes collaborators
Loading University of Paris Descartes collaborators